Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
TIANYIN PHARMACEUTICAL CO., INC. (TPI)
|
Add to portfolio |
|
|
|
| Price: |
$0.16
| | Metrics |
| OS: |
29.4
|
M
| |
-4
|
% ROE
|
| Market cap: |
$4.71
|
M
| |
-2
|
% ROIC
|
|
Net cash:
|
$12.2
|
M
| |
$0.42
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$475.7
|
k
| |
-15.8
|
x EV/EBITDA
|
|
EBIT
|
($2.1)
|
M
| |
|
|
| EPS |
($0.13)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Jun-30-14 | Jun-30-13 | Jun-30-12 | Jun-30-11 | Jun-30-10 | Jun-30-09 | Jun-30-08 | Jun-30-07 |
| Revenues | 46.6 | 67.5 | 69.6 | 95.2 | 63.9 | 42.9 | 33.5 | 20.2 |
| Revenue growth | -31.0% | -3.0% | -26.9% | 48.9% | 49.1% | 28.2% | 65.6% | |
| Cost of goods sold | 30.7 | 41.5 | 45.3 | 52.7 | 30.6 | 21.5 | 18.8 | 12.3 |
| Gross profit | 15.9 | 26.0 | 24.3 | 42.5 | 33.3 | 21.4 | 14.7 | 7.9 |
| Gross margin | 34.1% | 38.5% | 35.0% | 44.6% | 52.2% | 49.8% | 43.8% | 39.2% |
| Selling, general and administrative | | | | | | | | 1.8 |
| Sales and marketing | 7.8 | 11.4 | 10.7 | 17.7 | 12.8 | 7.8 | 4.7 | |
| Research and development | 0.9 | 0.9 | 0.9 | 1.1 | 0.9 | 0.3 | 0.2 | 0.1 |
| General and administrative | 4.4 | 4.4 | 4.3 | 5.6 | 4.9 | 3.5 | 2.1 | |
| EBITA | 3.5 | 10.1 | 9.2 | 18.7 | 14.7 | 9.7 | 7.6 | 5.0 |
| EBITA margin | 7.5% | 15.0% | 13.3% | 19.7% | 23.1% | 22.7% | 22.6% | 24.8% |
| Amortization of intangibles | 0.8 | 0.8 | 0.7 | 0.6 | | | | |
| EBIT | 2.7 | 9.3 | 8.5 | 18.1 | 14.7 | 9.7 | 7.6 | 5.0 |
| EBIT margin | 5.8% | 13.8% | 12.3% | 19.0% | 23.1% | 22.7% | 22.6% | 24.8% |
| Pre-tax income | -0.6 | 9.0 | 8.6 | 19.7 | 14.5 | 9.5 | 7.2 | 4.8 |
| Income taxes | 0.2 | 2.4 | 2.4 | 4.1 | 2.6 | 1.6 | 1.2 | 0.8 |
| Tax rate | | 26.8% | 27.5% | 20.8% | 18.1% | 17.2% | 17.1% | 17.5% |
| Net income | -0.6 | 6.7 | 6.4 | 15.5 | 11.9 | 7.9 | 6.0 | 3.9 |
| Net margin | -1.4% | 9.9% | 9.1% | 16.3% | 18.6% | 18.4% | 17.8% | 19.5% |
| |
| Diluted EPS | ($0.02) | $0.23 | $0.22 | $0.52 | $0.40 | $0.32 | $0.00 | $0.31 |
| Shares outstanding (diluted) | 29.4 | 29.3 | 29.3 | 29.7 | 30.1 | 24.8 | 19.1 | 12.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|